Target intelligence / Profile preview

microRNA 4759 (miR-4759)

Target
miR-4759
Molecular classification
microRNA (miRNA), Non-coding RNA, Regulatory RNA
01

Overview

microRNA 4759 (miR-4759) is a small, non-coding RNA belonging to the microRNA family. Identified as a novel direct negative regulator of PD-L1 in breast cancer, miR-4759 binds to two conserved sites within the 3′-UTR of the PD-L1 gene and inhibits its expression. Overexpression of miR-4759 in breast cancer cells sensitizes them to cytotoxic T-cell–mediated killing, suppresses tumor growth in immunocompetent mice, and is associated with better overall survival in human breast cancer. miR-4759 is predominantly downregulated in breast tumors versus normal tissue, particularly in triple-negative subtypes. Its primary therapeutic interest is as an immune-sensitizing agent, with clinical application being the delivery of miR-4759 mimics to suppress PD-L1 and enhance anti-tumor immunity

Other names
hsa-mir-4759MIR4759miR-4759
02

Mechanism of action

Post-transcriptional repression of target mRNAs Direct binding to the 3′-UTR of the PD-L1 (CD274) gene transcript, leading to decreased PD-L1 expression on tumor cells and sensitization to immune-mediated killing

03

Biological functions

Post-transcriptional gene regulationRegulation of immune checkpoint (notably downregulation of PD-L1)Promotion of anti-tumor immunitySuppression of tumor growth via enhancement of immune cell-mediated cytotoxicity
04

Disease associations

Cancer (specifically breast cancer, especially triple-negative subtypes)Immune evasion by tumorsmiR-4759 expression is downregulated in breast tumors relative to normal tissue and linked to poor survival, implicating it as a tumor suppressor in this context
05

Safety considerations

Off-target effects are a general concern for therapeutic microRNA manipulation.Systemic modulation of immune checkpoint pathways (via miR-4759) could increase risk for autoimmune phenomena, but no specific preclinical safety data are noted for miR-4759.Challenges include effective and specific delivery of miRNA mimics to tumor cells.
06

Biomarkers

miR-4759 expression levels (potential biomarker for breast cancer prognosis and response to immunotherapy targeting the PD-1/PD-L1 axis)PD-L1 expression (inversely correlated with miR-4759 levels)

Beyond the preview

Go deeper on microRNA 4759 (miR-4759).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on microRNA 4759 (miR-4759).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call